Search company, investor...

Aprea Therapeutics

aprea.com

Founded Year

2003

Stage

IPO | IPO

Total Raised

$112.84M

Date of IPO

10/3/2019

Market Cap

0.02B

Stock Price

0.38

About Aprea Therapeutics

Aprea Therapeutics (NASDAQ:APRE) is a biopharmaceutical company focused on the discovery and development of anticancer compounds that reactivate the tumor suppressor protein. p53. The Company's lead drug candidate is APR-246, a small molecule in clinical development for myelodysplastic syndromes (MDS) and high-grade serious ovarian cancer.

Headquarters Location

535 Boylston Street

Boston, Massachusetts, 02116,

United States

609-510-4718

Missing: Aprea Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Aprea Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Aprea Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aprea Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

838 items

Aprea Therapeutics Patents

Aprea Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Programmed cell death
  • Proteins
  • Transcription factors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/21/2011

6/23/2015

Autoimmune diseases, Neurological disorders, Syndromes, Rheumatology, Rare diseases

Grant

Application Date

1/21/2011

Grant Date

6/23/2015

Title

Related Topics

Autoimmune diseases, Neurological disorders, Syndromes, Rheumatology, Rare diseases

Status

Grant

Latest Aprea Therapeutics News

Why Compass Shares Are Trading Higher By Over 56%? Here Are 63 Stocks Moving In Fridays Mid-Day Session

Nov 11, 2022

Gainers Snail, Inc. SNAL shares jumped 74.9% to $3.9350 after the company announced a $5 million share repurchase program. AGBA Acquisition Limited AGBA gained 70% to $9.35 after dipping 50% on Thursday. AGBA Acquisition announced approval of business combination and ability of stockholders to withdraw ordinary shares tendered for redemption. Compass, Inc. COMP surged 56% to $3.80. Compass posted a wider-than-expected loss for its third quarter, while sales topped estimates. Mercurity Fintech Holding Inc. MFH jumped 39% to $0.6994 afetr dropping 26% on Thursday. Hillstream BioPharma, Inc. HILS gained 35.8% to $0.5092. TransAct Technologies Incorporated TACT surged 33% to $5.55 after the company swung to a profit for the third quarter. 8i Acquisition 2 Corp. LAX jumped 31.8% to $7.26 after dropping 43% on Thursday. Telos Corporation TLS gained 31.2% to $4.58. Kalera Public Limited Company. KAL climbed 31% to $0.1061 after gaining 10% on Thursday. Kalera recently said it sees Q3 net sales of $1.6 million. Kaleyra, Inc. KLR gained 30% to $0.8446. Kaleyra extended Oracle partnership to leverage Oracle Cloud. uCloudlink Group Inc. UCL rose 29.9% to $1.65. uCloudlink Group is expected to report Q3 financial results on November 16, 2022. Sono Group N.V. SEV gained 29.6% to $1.4650. Sight Sciences, Inc. SGHT shares gained 29.4% to $10.82 after the company posted upbeat Q3 sales and raised FY22 revenue outlook. Avadel Pharmaceuticals plc AVDL surged 27.1% to $7.89. Avadel Pharmaceuticals posted a Q3 loss of $0.33 per share. Versus Systems Inc. VS jumped 26% to $3.7813 after jumping over 40% on Thursday. The company recently announced a 1-for-15 reverse stock split to aid compliance with Nasdaq listing requirements. Doximity, Inc. DOCS shares climbed 24.8% to $32.85 after the company reported better-than-expected Q2 results. Tantech Holdings Ltd TANH gained 23.6% to $2.88. Century Aluminum Company CENX gained 22.4% to $9.74. Century Aluminum recently posted a Q3 loss of $0.34 per share. LifeMD, Inc. LFMD jumped 21.6% to $2.53 following strong quarterly earnings. Tuniu Corporation TOUR climbed 21.5% to $0.84. GlycoMimetics, Inc. GLYC gained 21.4% to $1.1899. GlycoMimetics recently posted a Q3 loss of $0.16 per share. NanoString Technologies, Inc. NSTG jumped 21.2% to $8.87. NanoString Technologies recently reported worse-than-expected Q3 results. Agora, Inc. API gained 20% to $3.65. a.k.a. Brands Holding Corp. AKA jumped 19.9% to $1.81 following strong quarterly sales. Zai Lab Limited ZLAB gained 19.6% to $36.34. Zai Lab reported better-than-expected Q3 sales results. Polestar Automotive Holding UK PLC PSNY gained 19.4% to $5.45 after the company reported Q3 earnings results. KE Holdings Inc. BEKE rose 18.3% to $13.41 after gaining 9% on Thursday. PDF Solutions, Inc. PDFS gained 17.8% to $29.57 following better-than-expected quarterly results. Matterport, Inc. MTTR gained 17.5% to $3.56 after the company reported better-than-expected Q3 sales results. The company also issued Q4 and FY22 sales guidance above analyst estimates. Aurora Cannabis Inc. ACB jumped 17.2% to $1.5350. Aurora Cannabis reported Q1 sales of C$49.3 million. GDS Holdings Limited GDS rose 17% to $12.87 after climbing 20% on Thursday. AvePoint, Inc. AVPT jumped 16.4% to $4.61 following strong quarterly sales. Cosmos Holdings Inc. COSM gained 15% to $0.1322 after jumping around 58% on Thursday. Beam Global BEEM rose 14.8% to $14.98 after reporting Q3 results. Alcoa Corporation AA gained 14.7% to $50.35. Piedmont Lithium Inc. PLL gained 13.4% to $70.28. Mister Car Wash, Inc. MCW jumped 13.1% to $10.47 following strong quarterly results. Redfin Corporation RDFN gained 10.6% to $4.77. Asana, Inc. ASAN rose 8.3% to $20.35 after jumping 17% on Thursday. Prudential plc PUK shares rose 7.7% to $23.59 after gaining 7% on Thursday. Xinyuan Real Estate Co., Ltd. XIN rose 7.4% to $0.43. AD Losers Blue Apron Holdings, Inc. APRN fell 31% to $1.1999. Blue Apron filed for offering of up to $30 million of common stock. AirSculpt Technologies, Inc. AIRS dropped 29.2% to $3.35 after the company reported worse-than-expected Q3 results. East Stone Acquisition Corporation ESSC fell 28.1% to $7.17. Fast Radius, Inc. FSRD shares fell 27.8% to $0.1881. Fast Radius shares jumped 156% on Thursday after the company announced the United States Bankruptcy Court for the District of Delaware has approved all of the first-day motions related to the company's voluntary Chapter 11 petitions filed on November 7, 2022. Brilliant Earth Group, Inc. BRLT shares fell 24.4% to $6.07 after the company issued 2022 sales guidance below estimates. Science 37 Holdings, Inc. SNCE dropped 24% to $0.95 after the company posted downbeat Q3 results and lowered sales guidance. Entera Bio Ltd. ENTX fell 22.4% to $0.48. Aprea Therapeutics, Inc. APRE dipped 21.8% to $0.4101. Aprea Therapeutics recently posted a Q3 loss of $0.12 per share. Kintara Therapeutics, Inc. KTRA dropped 21.6% to $0.0816 after the company announced a 1-for-50 reverse stock split. Rallybio Corporation RLYB declined 19.5% to $5.39. Rallybio announced pricing of $50 million public offering of 5 million shares of common stock at a price of $6 per share. Expensify, Inc. EXFY dropped 19.2% to $10.46 after the company reported worse-than-expected Q3 EPS and sales results. Ryan Specialty Holdings, Inc. RYAN dropped 17.3% to $36.77 after the company reported worse-than-expected Q3 results. Multiple analysts lowered their price targets on the stock following the report. FlexShopper, Inc. FPAY fell 16.3% to $1.2794 after the company reported a year-over-year drop in Q3 sales. Barfresh Food Group, Inc. BRFH fell 16.3% to $1.4306. Barfresh reported Q3 sales of $2.4 million. RedHill Biopharma Ltd. RDHL shares fell 15.7% to $0.5201. RedHill Biopharma recently issued H1/22 highlights and Q3/22 estimates. SHF Holdings, Inc. SHFS dipped 15.3% to $3.21. The Oncology Institute, Inc. TOI dropped 15% to $2.4950. Guggenheim maintained The Oncology Institute with a Buy and lowered the price target from $7 to $6. Tattooed Chef, Inc. TTCF fell 14.6% to $3.7550 after the company lowered its FY22 sales guidance below analyst estimates. EverCommerce Inc. EVCM dropped 13.9% to $7.14 after the company reported worse-than-expected Q3 results. Several analysts lowered their price targets on the stock following the report. EpicQuest Education Group International Limited EEIQ shares fell 12.9% to $1.56 after jumping 72% on Thursday. ASP Isotopes Inc. ASPI shares fell 11.6% to $2.3591 after dropping 33% on Thursday. ASP Isotopes announced $5 million pricing of initial public offering of 1.25m shares of common stock at a price of $4 per share. GoHealth, Inc. GOCO fell 8.2% to $0.4495 after posting downbeat Q3 sales. AD

Aprea Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aprea Therapeutics Rank

Aprea Therapeutics Frequently Asked Questions (FAQ)

  • When was Aprea Therapeutics founded?

    Aprea Therapeutics was founded in 2003.

  • Where is Aprea Therapeutics's headquarters?

    Aprea Therapeutics's headquarters is located at 535 Boylston Street, Boston.

  • What is Aprea Therapeutics's latest funding round?

    Aprea Therapeutics's latest funding round is IPO.

  • How much did Aprea Therapeutics raise?

    Aprea Therapeutics raised a total of $112.84M.

  • Who are the investors of Aprea Therapeutics?

    Investors of Aprea Therapeutics include Janus Henderson Investors, HealthCap Venture Capital, Versant Ventures, Sectoral Asset Management, 5AM Ventures and 10 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.